Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Sep 1, 2025
Abpro Holdings, Inc. (NASDAQ:ABP) is a biotechnology company founded in 2004 and headquartered in Woburn, Massachusetts. The company went public in March 2022 and was formerly known as Abpro Corporation before changing its name in November 2024. Abpro specializes in developing antibody therapeutics targeting immuno-oncology, ophthalmology, and autoimmune diseases through its proprietary <b>DiversImmune</b> platform technology.
Latest newsMore news →
Miles Suk resigned as Chief Executive Officer of Abpro Holdings, Inc., effective August 19, 2026, and M. Fatih Karatas was appointed Interim Chief Executive Officer, effective August 25, 2026.27d agoAbpro Holdings, Inc. was delisted from NASDAQ on May 28, 2026, for failing to comply with Rule 5550(b)(1) regarding minimum equity.109d ago